Acorda Therapeutics’ rebuilding plan just suffered another setback, leaving the fate of one of the experimental Parkinson’s disease drugs that is closest to market unclear. Ardsley, NY-based Acorda (NASDAQ: ACOR) said Wednesday morning that it has seen troubling safety problems in a Phase 3 trial of its experimental Parkinson’s disease drug tozadenant. Acorda reported cases […]
NYS Entity Status
NYS Filing Date
MAY 07, 2014
NYS DOS ID#
8 LINCOLN AVENUE
ARDSLEY, NEW YORK, 10502
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2014 - AQEL MANAGEMENT INC.
Around the Web
- Acorda Takes Another Hit, Reports Patient Deaths in Parkinson’s Study
By Ben Fidler - Wednesday Nov 15, 2017
- At Walmart Academy, Training Better Managers. But With a Better Future?
By MICHAEL CORKERY - Tuesday Aug 8, 2017
A new program for store supervisors and department managers may make them better employees but may not help them reach the middle class.
- FDA Refuses to Review Acorda Parkinson’s Drug, Shares Tumble
By Ben Fidler - Tuesday Aug 29, 2017
The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is critical to the company’s future. Acorda (NASDAQ: ACOR) said this morning that the FDA has sent the Ardsley, NY, company a […]
- Growth Is the New HP Way, for Now
Thursday Aug 24, 2017
What to do with a no-growth technology company that actually manages to grow? That is the conundrum facing HP Inc.’s investors.
- Sunday Routine: How Sheryll Durrant, Urban Farmer, Spends Her Sundays
By SHIVANI VORA - Friday Sep 15, 2017
The resident manager of the Kelly Street Garden, in South Bronx’s Longwood neighborhood, sleeps in and spends time with her husband and teenage son.
- Ryder Trucks Launches Campaign With 'Inc.'
Tuesday Sep 19, 2017
"The campaign underscores how truck owners are essentially dumping cash all over America's highways from all the hidden costs required in maintaining a private fleet," Ryder's Karen Jones tells"Marketing Daily."